News

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines…

1 year ago

Stem Pharm and Verge Genomics Form Collaboration Focused on Parkinson’s Disease

MADISON, Wis., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Stem Pharm, Inc., a drug discovery platform company leveraging 3D neuro-immune organoids…

1 year ago

PetVivo Holdings, Inc. to Exhibit at 2023 American College of Veterinary Surgeons Conference

MINNEAPOLIS, MN, US, Oct. 10, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging…

1 year ago

Leading Federal Health IT Executive Appointed to Strategic Advisory Role at DLH

ATLANTA, Oct. 10, 2023 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of…

1 year ago

Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors

-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE…

1 year ago

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

DALLAS, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on…

1 year ago

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023)MADRID, Spain and BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics,…

1 year ago

Kamada Provides Corporate Update on its Israel Operations

REHOVOT, Israel, and HOBOKEN, N.J., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage…

1 year ago

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria…

1 year ago

Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director

Christal Mickle transitions back to Chief Development Officer CELEBRATION, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS:…

1 year ago